|
|
Article: Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. Announce Availability of 2 mg ABILIFY(R) (aripiprazole) Tablet and Nonrefrigerated Oral Solution.
- Article from:
- PR Newswire
- Article date:
- February 7, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Newly Available Options Equip Physicians with Increased Flexibility when Customizing Treatment to Address Specific Needs of Adults with Schizophrenia or Bipolar I Disorder
PRINCETON, N.J. and TOKYO, Feb. 7 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced two newly available options of ABILIFY(R) (aripiprazole) -- a 2 mg tablet strength and a nonrefrigerated oral solution (1 mg/mL). The ABILIFY 2 mg tablet equips physicians with an additional dosage strength to help them titrate patients to an effective dose. The nonrefrigerated oral solution formulation allows greater convenience for adults who are ...